HCPCS code J1040: Deleted methylprednisolone acetate 80 mg guide

Key Takeaways

HCPCS code J1040 (methylprednisolone acetate, 80 mg) was deleted effective April 1, 2024, in an off-cycle CMS update that also deleted J1020 (20 mg) and J1030 (40 mg); none of the three per-dose codes are billable anymore.

All three were replaced by a single new code, J1010 (injection, methylprednisolone acetate, 1 mg), billed per milligram administered: an 80 mg dose is J1010 x 80 units, 40 mg is x 40 units, and 20 mg is x 20 units.

There is no dose-specific replacement to search for. Submitting J1040, J1020, or J1030 on a claim dated April 1, 2024 or later is rejected automatically; the fix is rebilling under J1010 with the correct unit count.

J1010 does not need annual re-identification the way the old dose codes did; only the quarterly ASP-based rate and the NDC for the vial concentration used still need routine verification.

Practice management software like Pabau keeps injection documentation, dose, route, site, and indication, organized in one patient record, giving injection-based practices a clear paper trail when they bill for procedures like this.

Most billing rejections tied to methylprednisolone acetate injections trace back to one mistake: submitting a dose-specific code that no longer exists. HCPCS code J1040 (the 80 mg dose) was deleted from the HCPCS Level II code set effective April 1, 2024. At the same time, that off-cycle CMS update also removed J1020 (20 mg) and J1030 (40 mg).

All three were combined into one code, J1010, billed per milligram administered. As a result, an 80 mg dose is now billed as J1010 x 80 units, not a fixed per-dose code.

For rheumatologists, orthopedic practices, and corticosteroid-injection-heavy practices, the fix is a one-time charge master update rather than a recurring lookup. In short, once J1010 replaces the old dose-specific codes, the unit count simply follows whatever dose is documented in the chart.

What is HCPCS code J1040?

HCPCS code J1040 was a Level II Healthcare Common Procedure Coding System code that described a single injection of methylprednisolone acetate at the 80 mg dose. Specifically, methylprednisolone acetate, sold under the brand name DepoMedrol by Pfizer, is a long-acting corticosteroid administered by intramuscular, intra-articular, or intralesional injection.

The Centers for Medicare and Medicaid Services (CMS) maintains HCPCS Level II J-codes to report drugs and biologicals not covered by CPT. This category includes injectable corticosteroids like this one. See the CMS HCPCS overview for the full code-set structure.

J1040 was part of a three-code dose series alongside J1020 (20 mg) and J1030 (40 mg). The full descriptor read: Injection, methylprednisolone acetate, 80 mg.

All three codes were deleted from the HCPCS Level II code set effective April 1, 2024. They were replaced by a single code, J1010, billed per milligram administered. As a result, none of the three original dose-specific codes are valid billing codes for any payer using current HCPCS files.

J1040 code status: Deleted and what that means for billing

J1040, along with J1020 and J1030, was deleted from the HCPCS Level II code set effective April 1, 2024. It was replaced by a single code, J1010, billed per milligram administered. However, a deleted HCPCS code is not just outdated. It is actively invalid.

When a claim reaches a payer’s adjudication system carrying J1040, J1020, or J1030, the system does not evaluate medical necessity, check documentation, or apply the patient’s benefits. Instead, it rejects the claim outright because the code does not exist in the current HCPCS master file. As a result, the rejection is immediate and automatic.

Charge master and superbill audit risk

This creates a real problem for any practice that has not audited its charge master or superbill since J1040 was removed. For example, providers using legacy billing templates, outdated EHR code lists, or paper encounter forms that pre-date the deletion are at risk. Their claims may simply never process.

The downstream effects include delayed reimbursement, rework costs, and the administrative burden of resubmission. In addition, the same audit discipline applies across the charge master, not just J-codes. Deleted or revised supply codes like A4326 and paired diagnosis codes like M71.9 need the same periodic review.

• Claim rejection: Any claim carrying J1040, J1020, or J1030 is rejected at adjudication with an invalid-code edit.
• No payment path: Rejected claims do not enter the appeals process; the code must be corrected and resubmitted.
• Audit exposure: Practices that continue using deleted codes may attract payer scrutiny during billing audits.
• Charge master risk: Outdated superbills or EHR charge capture lists are the most common source of deleted-code errors.
• One-code fix: Providers rebill under J1010, with units equal to the milligrams administered, rather than hunting for a new dose-specific code.

Updating superbills and templates to J1010

The practical fix is a charge master review. Specifically, any superbill line item, EHR order, or billing template that references J1040, J1020, or J1030 must be updated to J1010. This should happen before the next claim is submitted.

Good medical forms that capture the dose administered in milligrams at point of care make this switch straightforward. That is because the mg figure becomes the J1010 unit count directly.

J1020, J1030, J1040 crosswalk: The single J1010 replacement

Methylprednisolone acetate injection billing is still dose-driven, but the coding mechanics changed on April 1, 2024. Instead of three separate codes for three doses, CMS combined J1020, J1030, and J1040 into a single code, J1010 (injection, methylprednisolone acetate, 1 mg). This new code is billed in units equal to the milligrams administered.

In addition, AAPC’s HCPCS code database confirms J1040’s deleted status effective April 1, 2024, alongside J1020 and J1030, and lists J1010 as the replacement.

Unit-based billing mechanics for J1010

The billing principle has not changed, only the mechanics have. The unit count must reflect the milligrams actually administered, not the vial size ordered. For example, consider a provider who draws 80 mg from a 40 mg/mL vial and administers it as a single injection. In that case, the claim reports J1010 x 80 units.

Billing fewer units than the documented dose, or still billing under a deleted code like J1030, misrepresents the service. As a result, the claim either underpays the practice or fails at adjudication outright.

Rate updates and the off-cycle deletion timeline

Always verify the current J1010 payment rate against the CMS fee schedule lookup before submitting claims, since ASP-based drug rates update quarterly. Unlike the old per-dose codes, J1010 itself does not need re-identifying each year.

This was an off-cycle quarterly update rather than CMS’s standard January 1 annual HCPCS revision. Therefore, periodic checks should focus on the rate and the NDC on file, not on whether the code has changed again. Keeping charge masters current, whatever practice management software a billing team uses, reduces the risk of submitting with an outdated code.

Drug description: Methylprednisolone acetate 80 mg and clinical indications

Methylprednisolone acetate is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. The acetate salt provides a depot effect, meaning absorption is slower than with water-soluble forms. As a result, it is suitable for intra-articular, intramuscular, and intralesional administration where sustained local or systemic effect is desired. DepoMedrol is the most recognized brand formulation.

The 80 mg dose, billed today as J1010 x 80 units, is associated with higher-demand clinical scenarios. Correct ICD-10 pairing requires the documented indication to match the code selected. For instance, practices serving dermatology and rheumatology practices, as well as sports medicine practices administering joint injections directly, see the full spectrum of these indications regularly.

• Rheumatoid arthritis (large joint flares): Intra-articular injection for acute joint inflammation where oral therapy is insufficient.
• Bursitis: Injection into an inflamed bursa to reduce local inflammation.
• Tendinitis: Peritendinous injection for conditions like supraspinatus tendinitis or bicipital tendinitis.
• Acute gouty arthritis: Intra-articular or IM injection during acute flares when colchicine is contraindicated.
• Allergic conditions: High-dose IM injection for severe allergic reactions or exacerbations of allergic dermatitis.
• Dermatologic conditions: Intralesional injection for hypertrophic scars, keloids, and psoriatic plaques.
• Systemic lupus erythematosus flares: Adjunctive IM administration during acute disease activity.

Accurate clinical indication documentation is not just a compliance exercise. Payer LCD requirements for corticosteroid injections typically require the diagnosis to be supported by objective findings in the medical record. This is the same standard that applies to a dermatologic diagnosis like L26. In short, a documented injection without a corresponding ICD-10-coded diagnosis supporting medical necessity is a denial waiting to happen.

ICD-10 diagnosis codes used with J1040 and its replacements

Correct ICD-10-CM linkage is a prerequisite for claim payment, not an optional addition. Payers therefore cross-reference the submitted HCPCS code against the diagnosis code to assess medical necessity.

For methylprednisolone acetate injections, the ICD-10 code must reflect the condition being treated, the anatomical site where possible, and laterality where required by the code set. Related rheumatology diagnoses follow this same laterality logic. For example, M05.9 works the same way when the record documents seropositive disease instead.

Where a more specific ICD-10-CM code is available (e.g., M06.011 for rheumatoid arthritis of right shoulder), use the highest specificity the documentation supports. Otherwise, submitting M06.9 when the record clearly documents the joint and laterality leaves money on the table. It may also trigger a medical necessity query on certain LCD-governed claims.

In addition, a procedure-to-diagnosis crosswalk tool and your MAC’s published LCD policies are the fastest way to confirm the correct pairing for your jurisdiction.

Medicare Part B coverage and reimbursement for J1040 claims

Medicare Part B covers injectable drugs, including corticosteroids like methylprednisolone acetate, under the drug benefit when administered by a qualified provider in an office or outpatient setting. In turn, reimbursement for HCPCS J-code injectable drugs is based on the Average Sales Price (ASP) approach.

CMS updates ASP-based rates quarterly, meaning the per-mg J1010 payment rate changes four times per year. Since J1010 is billed in units equal to the mg administered, that quarterly rate applies directly to whatever dose is documented.

Always verify the current rate using the CMS fee schedule lookup tool referenced earlier. Otherwise, the practice risks relying on a rate published more than one quarter ago.

Because HCPCS codes J1040, J1030, and J1020 are all deleted, Medicare will not process any claim that carries any of them. The Medicare claims processing system runs automated code-validity edits. A deleted code fails those edits at intake, and the claim is returned as unprocessable.

This is not a denial that can be appealed. Instead, the claim must be corrected to J1010, with units equal to the mg administered, and resubmitted within the applicable timely filing limit.

Payer-specific coverage policies and prior authorization

Commercial payers handle methylprednisolone acetate injection coverage differently from Medicare. In fact, this is where many practices run into secondary denials, even after correcting the deleted-code error. The considerations below cover LCD nuances, Medicaid carve-outs, and prior authorization thresholds specific to depot corticosteroid injections.

For instance, the same scrutiny shows up around other time-sensitive codes, like 99140 for emergency anesthesia, where documentation timing is just as critical to reimbursement.

• Local Coverage Determinations (LCDs): Medicare Administrative Contractors (MACs) publish LCDs for corticosteroid joint injections. These specify covered diagnoses, frequency limits, and documentation requirements. Confirm your MAC’s active LCD before billing a high-frequency injection series.
• Medicaid: State Medicaid programs vary a lot. Some cover injectable corticosteroids under pharmacy benefit carve-outs rather than the medical benefit, requiring a different claim route. Confirm your state’s billing pathway before submitting a professional claim.
• Commercial payer prior authorization: Many commercial plans require prior authorization for depot corticosteroid injections when given more than two to three times per year to the same joint. Failure to obtain PA results in a post-service denial that is difficult to overturn.
• Managed care contracts: Some managed care agreements specify HCPCS code requirements that differ from Medicare fee-for-service rules. Review your contract addenda annually.

Maintaining HIPAA-compliant documentation that captures all payer-required elements reduces the risk of these secondary denials. The HIPAA-compliant clinical documentation requirements for injectable drug claims overlap closely with what LCDs require. Specifically, exact dose, route, indication, and provider credentials must all be present in the record.

Documentation requirements for methylprednisolone acetate injection billing

Documentation is where claims succeed or fail at audit. For methylprednisolone acetate injections specifically, payers want to see that the record supports both the HCPCS code selected and the ICD-10-CM code submitted alongside it. In fact, payers and the rheumatology billing community treat dose-specific documentation as a hard requirement, not a best practice.

What to capture at the point of injection

• Exact dose administered: The record must state the number of milligrams actually given, not the vial size ordered, since that mg figure becomes the J1010 unit count directly. If 80 mg was drawn from a 40 mg/mL vial, the note should confirm “80 mg methylprednisolone acetate administered” so the claim can report J1010 x 80 units.
• Route of administration: Intra-articular, intramuscular, intralesional, or intrabursal. Payers use route to validate the clinical rationale.
• Anatomical site: Specific joint, bursa, or lesion injected. “Left glenohumeral joint” is acceptable; “shoulder” is not specific enough for many LCDs.
• Clinical indication: The diagnosis supported by objective findings (imaging, range-of-motion measurement, prior treatment failure) that justifies the injection.
• Prescribing and administering provider: Name and NPI of both the ordering provider and the administering provider if different, particularly in multi-provider practices.
• Medical necessity narrative: For repeat injections, a brief notation of why the patient requires this injection again (ongoing flare, contraindication to other therapies, etc.) preempts LCD frequency-limit queries.
• Lot number and NDC where required: Some payers require the National Drug Code (NDC) on the claim line alongside the HCPCS J-code, particularly for Medicare Part B drug claims.

Turning documentation into consistent claims

Practices that capture structured intake and clinical documentation electronically are better positioned to meet these requirements consistently. As a result, Patient compliance documentation frameworks built into the clinical workflow ensure that injection encounter notes automatically include the fields payers require.

In addition, the best EMR software supports structured injection note templates that auto-populate dose, route, site, and indication fields at the point of care.

Reduce injection billing denials with Pabau

Practice management software like Pabau helps rheumatology and injection-based practices keep structured injection documentation, dose, route, site, and indication, organized and ready to support every claim.

Book a demo

Common billing errors for J1040 and how to avoid them

Deleted-code errors and dose mismatches account for the majority of claim rejections on methylprednisolone acetate claims. The table below combines the most common error types, their claim outcome, and the prevention action. In other words, it goes beyond a plain code definition into what goes wrong in practice and how to prevent it.

Using EHR integration that connects clinical documentation directly to claim generation helps eliminate the manual transcription errors (wrong dose, missing NDC, outdated code). These errors cause the majority of these rejections. Meanwhile, the practice management software your billing team uses should surface deleted-code alerts before a claim leaves the practice. It should not wait until the claim bounces back from the payer.

Verifying J1010 payment rates and NDC requirements

J1010 is the code, full stop. There is no dose-specific lookup left to do. That said, what is still worth bookmarking is where to verify the ASP-based payment rate each quarter and confirm nothing has changed again since this April 2024 update.

CMS’s standard annual HCPCS Level II update takes effect every January 1, but drug and biological codes can also change on the quarterly cycle: January, April, July, or October 1. That quarterly cycle is how this consolidation landed in April instead of January.

In addition, the free HCPCS lookup tool from PGM Billing uses current CMS data and is a reliable resource for confirming code status.

• CMS HCPCS Release and Code Sets page: Primary source; confirms J1010 is active and that J1020, J1030, and J1040 remain deleted, and flags any further code changes.
• CMS Physician Fee Schedule / ASP Pricing files: Confirms the current per-mg payment rate for J1010, updated quarterly.
• AAPC HCPCS code database: Lists J1010’s descriptor and confirms J1020, J1030, and J1040 as deleted codes.
• Your MAC’s website: Noridian, CGS, Palmetto GBA, and other MACs publish LCDs and billing articles specifying NDC and documentation requirements for J1010 claims in your jurisdiction.

For practices managing a high volume of injection billing, HIPAA compliance requirements intersect with HCPCS billing accuracy at the documentation layer. Structured electronic records that meet both requirements at the same time reduce duplicate administrative work. Likewise, the same documentation discipline carries over to related diagnoses like M32.8, where flare-specific detail is just as important to claim payment.

Conclusion

HCPCS code J1040 is deleted, along with J1020 and J1030: none of the three per-dose methylprednisolone acetate codes are billable anymore. As a result, any claim carrying one of them will be rejected automatically, with no payment path until the claim is corrected. The replacement is a single code, J1010, billed per milligram administered.

The fix requires three steps. First, audit your charge master to remove J1020, J1030, and J1040. Next, switch to J1010, with units equal to the mg documented in the chart. Finally, update your injection note templates to capture dose, route, site, indication, and NDC at point of care.

Practice management software like Pabau helps injection-based practices keep dose, route, site, and indication documentation organized in one patient record. This supports the audit trail payers expect for corticosteroid injection claims. To see how it works for your practice, book a demo.

Continue your research

Billing another joint-injection drug code? J7326 covers Gel-One viscosupplementation billing and fee-schedule lookups for a related joint therapy.

Pairing a local anesthetic with the injection? J0670 walks through mepivacaine hydrochloride billing rules that often apply alongside a joint procedure.

Need a documentation framework for audit-ready claims? HIPAA compliance checklist covers the record-keeping habits that hold up under payer review.

Frequently asked questions